当前位置: X-MOL 学术Blood › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival
Blood ( IF 20.3 ) Pub Date : 2024-04-24 , DOI: 10.1182/blood.2024024048
Bernard Douglas Maybury 1 , Lisa Jane James 1 , Neil Phillips 2 , Indrani Venkatadasari 3 , Iman Qureshi 4 , James William Elliot Riley 1 , Georgina Talbot 5 , Shivir Moosai 6 , Hannah Victoria Giles 1 , Nicola Chadderton 1 , James Dowds 1 , Pallav Rakesh 7 , Henry Crosland 1 , Aidan Haslam 1 , Sarah Lane 8 , Monica Vega Gonzalez 9 , David Davies 10 , George Cherian 8 , Amir Shenouda 11 , Praveen Kumar Kaudlay Sathyanarayana 3 , Jane Starczynski 1 , Zbigniew Rudzki 1 , Sridhar Chaganti 12
Affiliation  

A reciprocal t(3;8) :: fusion is common in large B-cell lymphoma (LBCL) with and disruption. These pseudo–double-hit cases are not adverse, whereas t(3;8)/ lymphoma has an inferior prognosis relative to other -rearranged LBCL.

中文翻译:


MYC/BCL6 重排大 B 细胞淋巴瘤中的 t(3;8) 检测可识别生存率较低的高风险亚组



倒数 t(3;8):: 融合在伴有破坏的大 B 细胞淋巴瘤 (LBCL) 中很常见。这些假性双重打击病例并不不利,而 t(3;8)/ 淋巴瘤相对于其他重排 LBCL 的预后较差。
更新日期:2024-04-24
down
wechat
bug